Please login to the form below

Not currently logged in
Email:
Password:

Realm Therapeutics appoints Sandy Zweifach as non-executive director

But Matthew Hammond and Daniel Hegglin retire

Biopharmaceutical company Realm Therapeutics has appointed Sandy Zweifach as a new non-executive director following the retirement of Matthew Hammond and Daniel Hegglin, both of whom served as non-executive directors.

Zweifach joins the biopharma with over 25 years’ experience in the life science industry, with a background in corporate partnering, business development, operations, private and public investing and capital raising.

He is founder, president and chief executive officer of Nuvelution Pharma, a company facilitating the clinical advancement of late stage pharmaceutical and biotechnology assets via a research and development risk-sharing approach that deploys capital and human resources.

Prior to this, Zweifach has served in several leadership roles, including CEO of Ascendancy Healthcare, CEO and president of Pathway Diagnostics and president and CFO of Epoch Biosciences.

Alex Martin, chief executive officer, Realm Therapeutics, said: “I am excited to welcome Sandy to the board.

“His background and experience in both the biopharmaceutical industry and investment banking will be helpful as we progress our pipeline and expand our optionality in 2018 and beyond.”

23rd November 2017

From: Sales

Share

Tags

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Page & Page and Partners

For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...

Latest intelligence

EU health fund
An EU emergency health fund to limit the impact of future crises
Leading finance experts propose an Emergency Health Financing Facility to limit the impact of future crises on the EU...
Mistrust in medical research: a patient perspective
The recent development of several COVID-19 vaccines has placed medical research firmly in the spotlight, highlighting public confusion and misinformation about clinical trials. Patient advocate, Trishna Bharadia reveals what the...
Real-world evidence: breaking boundaries in rare disease
Generating data for drug launches is a challenging process. In rare diseases, with small patient populations and high unmet need, evidence generation is even more complex. Consultant Sarah Poole and...

Infographics